Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30358060 | 0.91 | SCD5 (0.46) | HPGDGPR119USP2SMN1; SMN2EPHX2 | |
| SCHEMBL12727209 | 0.90 | HPGD (0.47) | HPGDGPR119USP2SMN1; SMN2EPHX2 | |
| SCHEMBL2344292 | 0.88 | HPGD (0.47) | HPGDGPR119USP2SMN1; SMN2EPHX2 | |
| SCHEMBL31586552 | 0.88 | HPGD (0.47) | HPGDGPR119USP2SMN1; SMN2EPHX2 | |
| SCHEMBL484799 | 0.86 | HSD17B10 (0.49) | HPGDGPR119USP2SMN1; SMN2EPHX2 | |
| SCHEMBL3245456 | 0.86 | GPR119 (0.46) | HPGDGPR119USP2SMN1; SMN2EPHX2 | |
| SCHEMBL29059015 | 0.85 | HSD17B10 (0.46) | HPGDGPR119USP2SMN1; SMN2EPHX2 | |
| SCHEMBL21513390 | 0.85 | EPHX2 (0.47) | HPGDGPR119USP2SMN1; SMN2EPHX2 | |
| SCHEMBL30161721 | 0.84 | SCD5 (0.43) | HPGDGPR119USP2SMN1; SMN2EPHX2 | |
| SCHEMBL1474868 | 0.84 | USP2 (0.49) | HPGDGPR119USP2SMN1; SMN2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724435-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12590090-B2 | Pyrimidine-and nitrogen-containing bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2026-03-31 | — | — | US | disclosed |
| CN-121574171-A | Difunctional protein degradation agent of direct targeting proteasome, preparation method and application thereof | 浙大城市学院 | 2026-02-27 | — | — | CN | disclosed |
| EP-4692079-A1 | CYP11A1 INHIBITOR AND USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025224085-A1 | COMPOUNDS CAPABLE OF ACTING ON S1R AS WELL AS ON SEH AND USES THEREOF | UNIVERSITAT DE BARCELONA (ES) | 2025-10-30 | — | — | WO | disclosed |
| EP-4631940-A1 | COMPOUND TARGETING PAN-KRAS PROTEIN DEGRADATION AGENT AND USE THEREOF | Betta Pharmaceuticals Co., Ltd. (CN) | 2025-10-15 | — | — | EP | disclosed |
| EP-4626554-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | Tiger Biotherapeutics Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4587446-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2025-07-23 | — | — | EP | disclosed |
| EP-4223750-B1 | NITROGEN-CONTAINING BICYCLIC COMPOUNDS WHICH CONTAIN PYRIMIDINE AS INTERLEUKIN 1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK-4) INHIBITORS TO BE USED IN THE TREATMENT OF INFLAMMATORY OR AUTOIMMUNE DISEASES | ASAHI KASEI PHARMA CORP (JP) | 2025-06-25 | — | — | EP | disclosed |
| CN-119954773-A | PSMA compounds, pharmaceutical compositions comprising the same and uses thereof | 苏州威智创科生物有限公司 | 2025-05-09 | — | — | CN | disclosed |
| EP-2906552-B1 | GUANIDINE SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-2861566-B1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | HOFFMANN LA ROCHE (CH) | 2016-12-21 | — | — | EP | disclosed |
| US-9315519-B2 | Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150259358-A1 | GUANIDINE SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-09-17 | — | — | US | disclosed |
| EP-2906552-A1 | GUANIDINE SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2015-08-19 | — | — | EP | disclosed |
| WO-2014059202-A1 | GUANIDINE SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-17 | — | — | WO | disclosed |
| WO-2012126275-A1 | SPIRO-CONTAINING DIHYDROPYRAZOLE COMPOUNDS | 山东亨利医药科技有限责任公司 (CN) | 2012-09-27 | — | — | WO | disclosed |
| EP-2358704-A1 | 7-azaspiro [3.5]nonane-7-carboxamide compounds as modulators of fatty acid amide hydrolase | Pfizer Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20100113465-A1 | 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS | PFIZER INC. | 2010-05-06 | — | — | US | disclosed |
| WO-2010049841-A1 | 7-AZASPIRO [3.5] NONANE-7-CARBOXAMIDE COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | PFIZER INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259358-A1 | GUANIDINE SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | KLKB1, TFPI, TFPI2 | HPGD 947/4885GPR119 2703/4885USP2 3554/4885 |
| US-20100113465-A1 | 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS | FAAH, FAAH2, APEH | HPGD 1697/4885GPR119 58/4885USP2 991/4885 |
| US-12590090-B2 | Pyrimidine-and nitrogen-containing bicyclic compound | IRAK1, IRAK4, IRAK2 | HPGD 3678/4885GPR119 1089/4885USP2 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.